Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.60 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HTR5A | P47898 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.50 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20122108 | 0.92 | ADORA3 (0.69) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL18358011 | 0.92 | ADORA3 (0.69) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL18352583 | 0.88 | HRH2 (0.52) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL18353052 | 0.86 | HRH2 (0.48) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL22757376 | 0.82 | ADORA3 (0.56) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL18353150 | 0.82 | HRH2 (0.51) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL22757377 | 0.81 | ADORA3 (0.58) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL12269992 | 0.80 | HRH2 (0.59) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL12269874 | 0.79 | HSP90B1 (0.59) | ADORA3HRH2HTR5AADORA1TMIGD3 | |
| SCHEMBL21758645 | 0.79 | ADORA3 (0.57) | ADORA3HRH2HTR5AADORA1TMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963450-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170002007-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002007-A1 | A3 ADENOSINE RECEPTOR AGONISTS | ADORA3, ADORA2B, ADORA1 | ADORA3 1/4885HRH2 204/4885HTR5A 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.